Home » Newsletters » BioWorld Science

BioWorld Science

April 29, 2002

View Archived Issues

Potent and selective CDK2 inhibitors with antitumor activity reported at ACS meeting

Major European launch for Viread

Lumigan approved by European Commission, introduced in three countries

Egis and Servier select new anxiolytic development candidate

Broad-spectrum beta-lactamase inhibitor useful in combination with penicillins and cephalosporins

New oxazolidinone AZD-2563 further characterized preclinically at ECCMID

Myfortic affords therapeutic exposure to active moiety in pediatric renal transplant patients

Caspase inhibitor protects against hepatic I/R injury in rat model

GSK's naratriptan will be developed and marketed by Sumitomo in Japan

Vascular remodeling following organ transplant effectively inhibited by new somatostatin analogue

Anti-TIRC7 MAb prevents acute cardiac allograft rejection

Vertex publishes first-quarter 2002 results

Lorus presents data on Virulizin at AACR

EMEA accepts Thalomid MAA for review

Companies collaborate to develop drugs targeting ABC transporters

Mylovenge designated orphan drug for treatment of multiple myeloma

Faslodex approved in U.S. for tamoxifen-resistant breast cancer

Trial initiated for NMP48 blood test for prostate cancer

Orphan Medical licenses rights to butamben

GenPhar develops vaccines for HIV, hepatitis B, hepatitis C and Marburg virus

Motilin antagonists useful for treatment of GI hypermotility

Pharmacyclics claims metallotexaphyrins and use in diagnosis and therapy

New Ilex compounds lower apolipoprotein and cholesterol levels

Cannabinoid receptor agonists reportedly useful for pain and Parkinson's disease

Agents for H. pylori infections designed at Yamanouchi

Inhibitors of JNKs useful for a wide range of conditions according to ARS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...